Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma
暂无分享,去创建一个
H. Goldschmidt | A. Ho | T. Moehler | H. Ludwig | R. Feneberg | M. Kropff | Jacek Hajda | A. Golenkov | Nuriet K. Khuageva | I. V. von Broen
[1] C. Ng,et al. A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer , 2010, Investigational New Drugs.
[2] B. Barlogie,et al. Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival. , 2009, Blood.
[3] M. Dimopoulos,et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG) , 2009, Leukemia.
[4] Axel Benner,et al. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. , 2008, Blood.
[5] D. Dingli,et al. Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.
[6] S. O’Day,et al. Phase I trial of imexon in patients with advanced malignancy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] R. Dorr,et al. Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines , 2007, Cancer Chemotherapy and Pharmacology.
[8] L. Gordon,et al. Imexon-Induced Apoptosis in Multiple Myeloma Tumor Cells Is Caspase-8 Dependent , 2004, Clinical Cancer Research.
[9] H. Goldschmidt,et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. , 2001, Blood.
[10] M. Briehl,et al. Induction of mitochondrial changes in myeloma cells by imexon. , 2001, Blood.
[11] M. Micksche,et al. Antitumor activity of imexon. , 1995, Journal of the National Cancer Institute.
[12] E. Hersh,et al. Sensitivity of multiple myeloma to imexon in the human tumor cloning assay. , 1994, Journal of the National Cancer Institute.
[13] A. Evens,et al. Oxidative stress and apoptosis: a new treatment paradigm in cancer. , 2006, Frontiers in bioscience : a journal and virtual library.
[14] M. Chirigos. Immune modulation and control of neoplasia by adjuvant therapy , 1978 .